Norbenzomorphan Framework as a Novel Scaffold for Generating Sigma2 Receptor/PGRMC1 Subtype-Selective Ligands

被引:22
|
作者
Sahn, James J. [1 ]
Hodges, Timothy R. [1 ]
Chan, Jessica Z. [1 ]
Martin, Stephen F. [1 ]
机构
[1] Univ Texas Austin, Dept Chem, 105 East 24th St,Stop A5300, Austin, TX 78712 USA
基金
美国国家卫生研究院;
关键词
1; 5-methanobenzazepines; norbenzomorphans; Sig2R; PGRMC1; sigma2; receptors; MULTICOMPONENT ASSEMBLY PROCESSES; MOLECULAR-PROPERTIES; PGRMC1; PROTEIN; DIVERSE; BINDING; LIBRARIES; STRATEGY;
D O I
10.1002/cmdc.201500551
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel structural class with high affinity and subtype selectivity for the sigma2 receptor has been discovered. Preliminary structure-affinity relationship data are presented showing that 8-substituted 1,3,4,5-tetrahydro-1,5-methanobenzazepine (norbenzomorphan) derivatives elicit modest to high selectivity for the sigma2 over the sigma1 receptor subtype. Indeed, piperazine analogue 8-(4-(3-ethoxy-3-oxopropyl)piperazin-1-yl)-1,3,4,5-tetrahydro-1,5-methanobenzazepine-2-carboxylate (SAS-1121) is 574-fold selective for the sigma2 over the sigma1 receptor, thereby establishing it as one of the more subtype-selective sigma2 binding ligands reported to date. Emerging evidence has implicated the sigma2 receptor in multiple health disorders, so the drug-like characteristics of many of the selective sigma2 receptor ligands disclosed herein, coupled with their structural similarity to frameworks found in known drugs, suggest that norbenzomorphan analogues may be promising candidates for further development into drug leads.
引用
收藏
页码:556 / 561
页数:6
相关论文
共 50 条
  • [21] 7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (σ2) receptor ligands
    Banister, Samuel D.
    Rendina, Louis M.
    Kassiou, Michael
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (12) : 4059 - 4063
  • [22] Novel spiropiperidines as highly potent and subtype selective σ-receptor ligands.: Part 1
    Maier, CA
    Wünsch, B
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (02) : 438 - 448
  • [23] Discovery of subtype-selective nmda receptor ligands: 4-benzyl-1-piperidinyalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists
    Wright, JL
    Gregory, TF
    Boxer, PA
    Meltzer, LT
    Serpa, KA
    Wise, LD
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (19) : 2815 - 2818
  • [24] Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
    Reubi, JC
    Waser, B
    Schaer, JC
    Laissue, JA
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (07) : 836 - 846
  • [25] The third transmembrane domains of the human B1 and B2 bradykinin receptor subtypes are involved in discriminating between subtype-selective ligands
    Fathy, DB
    Mathis, SA
    Leeb, T
    Leeb-Lundberg, LMF
    FASEB JOURNAL, 1997, 11 (09): : A1328 - A1328
  • [26] Novel 2(3H)-Benzothiazolones as Highly Potent and Selective Sigma-1 Receptor Ligands
    Saïd Yous
    Valérie Wallez
    Mirabelle Belloir
    Daniel H. Caignard
    Christopher R. McCurdy
    Jacques H. Poupaert
    Medicinal Chemistry Research, 2005, 14 : 158 - 168
  • [27] Novel 2(3H)-benzothiazolones as highly potent and selective sigma-1 receptor ligands
    Yous, S
    Wallez, V
    Belloir, M
    Caignard, DH
    McCurdy, CR
    Poupaert, JH
    MEDICINAL CHEMISTRY RESEARCH, 2005, 14 (03) : 158 - 168
  • [28] Decahydrobenzoquinolin-5-one sigma receptor ligands: Divergent development of both sigma 1 and sigma 2 receptor selective examples
    McLeod, Michael C.
    Aube, Jeffrey
    Frankowski, Kevin J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (23) : 5689 - 5694
  • [29] Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands
    Jean Reubi
    Beatrice Waser
    Jean-Claude Schaer
    Jean A. Laissue
    European Journal of Nuclear Medicine, 2001, 28 : 836 - 846
  • [30] 2-methyl-6-(phenylethynyl)-pyridine (MPEP): A novel potent, subtype-selective and systemically active antagonist at metabotropic glutamate receptor subtype
    Gasparini, F
    Lingenhoehl, K
    Flor, PJ
    Munier, N
    Heinrich, M
    Pagano, A
    Vranesic, I
    Biollaz, M
    Heckendorn, R
    Allgeier, H
    Varney, M
    Johnson, E
    Hess, SD
    Velicelebi, G
    Kuhn, R
    Urban, L
    BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 : U130 - U130